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Abstract
Context and Objective: Adipose tissue in insulin resistant subjects contains inflammatory cells and extracellular matrix
components. This study examined adipose pathology of insulin resistant subjects who were treated with pioglitazone or
fish oil.
Design, Setting and Participants: Adipose biopsies were examined from nine insulin resistant subjects before/after
treatment with pioglitazone 45 mg/day for 12 weeks and also from 19 subjects who were treated with fish oil (1,860 mg
EPA, 1,500 mg DHA daily). These studies were performed in a clinical research center setting.
Results: Pioglitazone treatment increased the cross-sectional area of adipocytes by 18% (p = 0.01), and also increased
capillary density without affecting larger vessels. Pioglitazone treatment decreased total adipose macrophage number by
26%, with a 56% decrease in M1 macrophages and an increase in M2 macrophages. Mast cells were more abundant in
obese versus lean subjects, and were decreased from 24 to 13 cells/mm2 (p = 0.02) in patients treated with pioglitazone, but
not in subjects treated with FO. Although there were no changes in total collagen protein, pioglitazone increased the
amount of elastin protein in adipose by 6-fold.
Conclusion: The PPARc agonist pioglitazone increased adipocyte size yet improved other features of adipose, increasing
capillary number and reducing mast cells and inflammatory macrophages. The increase in elastin may better permit
adipocyte expansion without triggering cell necrosis and an inflammatory reaction.
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Introduction
Insulin resistance develops with obesity and in the setting of
inadequate b-cell response, leads to type 2 diabetes (T2DM).
However, this process is complex, and many changes occur in the
adipose tissue of insulin resistant subjects, including the develop-
ment of a proinflammatory environment, characterized by an
influx of macrophages, an alteration in collagen and other
extracellular matrix (ECM) components, and hypoxia due to
decreased capillaries [1–4]. A leading hypothesis behind these
changes in adipose tissue is that increased adipocyte size in the
setting of a relatively rigid ECM leads to a compromised blood
supply, adipocyte necrosis, inflammation, and fibrosis [5].
A number of treatments have been used to decrease adipose
tissue inflammation and reduce insulin resistance. The PPARc-
agonist thiazolidinedione (TZD) drugs are used to treat T2DM.
TZDs improve peripheral insulin sensitivity, and have a spectrum
of anti-inflammatory properties, including a reduction in plasma
inflammatory markers, and a reduction in adipose tissue
macrophages [6–9]. Fish oils contain v-3 polyunsaturated fatty
acids (v-3 PUFA), which also have anti-inflammatory properties
[10,11] and have recently been shown to reduce plasma MCP-1
and adipose macrophages [12]. In some settings, v-3 PUFA
consumption resulted in an increase in adiponectin through a
PPARc-dependent mechanism [13,14].
In addition to macrophages, adipose tissue contains other
inflammatory cells, and several recent studies have identified mast
cells in adipose tissue of both mice and humans [15,16]. When
adipose mast cells were reduced through genetic or drug
manipulation, the metabolic profiles of mice were improved
[16]. In another study of humans, mast cell number was no
different between obese and lean humans, however the degree of
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mast cell activation was higher with obesity, and the overall
number of mast cells was higher in patients with T2DM [17].
In this study, we examined in greater depth the response of
adipose tissue macrophages to pioglitazone and fish oil treatment,
and to determine whether anti-inflammatory treatments would
reduce adipose mast cells. Pioglitazone, but not fish oil, treatment
resulted in a decrease in adipose tissue mast cells. In addition,
pioglitazone increased adipocyte size, increased adipose tissue
capillaries, and increased elastin in adipose tissue.
Materials and Methods
Ethics Statement
All research methods pertaining to human subjects were
approved by Institutional Review Boards from either University
of Arkansas for Medical Sciences or the University of Kentucky.
This included obtaining consent from all participants using
consent forms that were approved by the above named
Institutional Review Boards.
Human Subjects
Three groups of participants were analyzed for this study to
determine the effects of obesity, pioglitazone treatment, and fish oil
treatment, as outlined in Table 1. To study the effects of obesity, a
group of subjects were recruited that included 7 lean, normal
glucose tolerant subjects, who were compared with 9 obese
subjects. For the study of pioglitazone, we analyzed the adipose
tissues of 9 subjects with obesity and impaired glucose tolerance
who had been treated with pioglitazone. These subjects were part
of a study on the effects of pioglitazone on adipose inflammation
and reported previously [6,7]. All of these subjects had impaired
glucose tolerance on a 75 g oral glucose tolerance test, and were
on no medications that could affect carbohydrate or lipid
metabolism. After a two week dose escalation, they were treated
with pioglitazone 45 mg per day for 10 weeks, which yielded a
65% increase in insulin sensitivity [18], and adipose biopsies were
performed by incision from the lower abdominal wall. In the nine
subjects treated with pioglitazone in this study, SI increased from
1.6 to 2.3 units (p,0.01), and 2 hr glucose decreased from 161 to
127 (p,0.05), and BMI increased from 32 to 33 (p,0.05), all
consistent with previous reports [18,19]. The third group of
subjects were obese, had at least 3 features of metabolic syndrome
(14 out of 19 had IGT), and all subjects had fat biopsies before
and after 12 weeks of treatment with fish oil (omega-3-Acid Ethyl
Esters, Lovaza, 4 g/day) for 12 weeks. As reported previously [12],
fish oil treatment did not affect insulin sensitivity or glucose
tolerance, and reduced triglycerides by 20% (p,0.05). All
participants signed consent forms that were approved by the
Institutional Review Boards from either the University of Arkansas
for Medical Sciences or the University of Kentucky. No
participants had any history of coronary disease, inflammatory
disease, the chronic use of any anti-inflammatory medication or
other medication likely to change adipocyte metabolism; none
were taking v-3 fatty acids supplements, and routine baseline labs
(liver function, creatinine, TSH, CBC) were normal.
Participants in this study were recruited from previously
reported clinical trials registered at clinicaltrials.gov, and a number
of publications have already come from these studies.
NCT00108615 (recruitment from 2004 through 2007) involved
participants treated with pioglitazone and different outcomes from
this study have been described previously [7,18,20–23].
NCT00470262 (recruitment from 2007 through 2012) also
involved participants treated with pioglitazone [24].
NCT00579436 (recruitment 2007 through 2013) involved the
treatment of subjects with fish oils or placebo [12]. The
examination of adipose mast cells, or the other features of adipose
tissue reported herein, were not part of the original design of these
studies.
Insulin sensitivity was measured with a frequently sampled IV
glucose tolerance test (FSIGT), which yields a measure of insulin
sensitivity (SI) that correlates well with glucose disposal rate from
the euglycemic clamp [4,25,26].
Histochemistry and immunohistochemistry. Adipose
samples were fixed in Bouin’s, paraffin embedded and cut into
5 mm thick sections. All macrophages were stained with CD68
(Dako, clone KP1,) followed by HRP-linked secondary antibody
and DAB substrate for color development (ImmPACT DAB,
Vector Labs, SK-4105). Identification of macrophage polarization
used a triple-staining procedure which used CD68, CD86 (Santa
Cruz Biotech, SC-28347, to identify M1 macrophages) and
CD206 (R and D Systems, AF2534, to identify M2 macrophages),
as described previously [1]. HRP-linked secondary antibodies and
three different chromogenic substrates were used to localize the
primary antibodies: ImmPACT NovaRED (Vector Labs, SK-
4805), ImmPACT VIP (Vector Labs, SK-4605), and TrueBlue
(KPL, 50-78-02). The Nuance multispectral microscopy camera
(PerkinElmer, 130925) was used to separate the chromogenic
substrates and identify cells stained with the different antibodies
and determine any co-localization.
The quantitation of blood vessels was performed by double
staining for endothelial cells (UEA lectin, Sigma: L8262) and alpha
smooth muscle actin (ASMA, Santa Cruz Biotech: SC130616), as
describe previously [4]. HRP-secondary antibody and ImmPACT
SG (Vector Labs, SK-4705) chromogenic substrate was used to
develop the staining for ASMA. Endothelial cells stained with
UEA were developed with streptavidin-HRP conjugate (Vector
Labs, SA-5004) followed by chromogenic substrate ImmPACT
NovaRED. The Nuance multispectral microscopy system was
used to separate the chromogenic substrates. Capillaries stained
only with the endothelial stain, whereas larger blood vessels were
identified by the ASMA ring around the endothelial cells [4].
Adipose mast cells were identified by staining for mast cell
tryptase (Santa Cruz Biotechnology, sc-33676) followed by
chromogenic color development using ImmPACT VIP.
Quantification of images
Single stained images (CD68 alone and Mast Cells) were
captured on Nikon 55i upright microscope using Nikon NIS
Elements software. Images were quantified in the NIS Elements
application by manual counting the number of cells. The total area
of adipose tissue was measured for each image and used to
normalize results as cells per mm2.
Multiple stained images (macrophage polarization and vessels)
were imaged on the Nuance system and individual spectral profiles
for each chromogen were used to separate the different antigens
and to create a multichannel image. This creates a image channel
for each chromogen. The different images were manually counted
with the number of cells being expressed as cells/mm2 of adipose
tissue.
Measurement of adipocyte size
Adipocyte size, elastin, and collagen were identified from
adipose tissue stained with Accustain Elastic Stain (Sigma,
HT25A-1KT). This technique stains elastin fibers black and
collagen pink, and adipocytes are easily identified as unstained
areas surrounded by collagen (Figure 1).
To measure adipocyte size, these images were analyzed by a
machine learning-based algorithm for quantification of adipocyte
Pioglitazone and Mast Cells
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cross-sectional area analysis (CSA). The image segmentation
algorithm have two major steps: 1) Machine learning based
automated detection of the geometric center of the adipocytes, 2) a
gradient vector flow based deformable model that adopts color
gradients to define the adipocyte boundaries and ECM. A detailed
description of the automated image segmentation algorithm can
be found in Methods S1. The accuracy of the automated
algorithm for adipocyte detection was determined by comparing
results to manually measured adipocyte areas. In a previous study
on the effects of fish oil on adipose inflammation [12], we
measured adipocyte size manually by sizing 300–600 cells in the
sections. To compare this method to the automated algorithm, we
compared the manually derived cell sizing to the automated
method. As shown in Figure S1, mean adipocyte size was highly
correlated between the two methods (r = 0.81, p,0.01). The
automated method has the advantage of high throughput analysis
of all the adipocytes on the section, between 8000–12000 cells,
which is more than the number of cells that can be practically
measured manually. The automated method improves accuracy,
avoids the problem of measuring cells in non-representative fields,
and also saves tremendous amount of time and labor. A similar
automated approach was recently validated for quantification of
muscle fiber CSA [27].
Quantitation of collagen and elastin
As described above, the Accustain identified collagen and elastin
based on their pink and black staining, respectively. To quantify
the amount of collagen and elastin in the tissue section, the same
Table 1. Baseline characteristics of study subjects.
Lean Obese Pioglitazone-treated Fish oil-treated
Number/female 7/5 9/8 9/8 19/13
Age (yr) 4062.8 46.5663.16 5062.6 48.862.3
% body fat 27.9563.5 45.1961.0 4162.4 44.462.7
BMI (kg/m2) 23.860.93 35.960.81 3261.5 33.462.3
Triglycerides (mg/dl) 70.669.14 140.1613.89 233648.5 147.367.7
Cholesterol (mg/dl) 19069.25 159.7612.89 218620.25 207.166.4
HDL (mg/dl) 6267.84 49.063.86 4862.3 53.564.2
LDL (mg/dl) 113.7569.1 82.4611.64 117618.1 125.966.1
Glucose fasting (mg/dl) 85.2563.59 92.263.51 9064.5 95.862.8
Glucose 2 hr (mg/dl) 121.9614.14 159.967.49 16168.7 167.866.6
HbA1c (%) 5.360.13 5.860.18 5.460.13 6.060.6
SI (61024 min21 [mU/ml]21) 7.0261.39 1.860.22 1.660.16 1.960.9
doi:10.1371/journal.pone.0102190.t001
Figure 1. Adipose immunohistochemistry for cell size and fibrosis. Adipose tissue was stained for elastin, as described in Methods. A. Elastin
stain, illustrating the outline of the adipocytes, elastin (black stain) and areas of fibrosis (pink). B. Identification of adipocytes using the image analysis
software, and the assignment of adipocyte area to the cells. C. Enhancement of image to bring out elastin (green). D. Enhancement of image to bring
out collagens (red).
doi:10.1371/journal.pone.0102190.g001
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techniques were used as described above, and explained in details
in Methods S1, but color thresholding of the ECM segmentation
was calculated based on the automated segmentation algorithm to
calculate the percent collagen and elastin [28,29].
Statistical Analysis
All data from samples were expressed as mean 6 SEM.
Statistical analysis was performed in either Microsoft Excel or
GraphPad Prism applications. Parametric t-tests were used to
detect significance between pre/post data or lean/obese data.
Macrophage polarization was tested using both ANOVA with
Tukey post-tests and t-test between different groups. ANOVA and
t-test produced identical results in terms of which groups were
significant. Histograms of adipocyte cross-sectional area were
analyzed in MATLAB with final graphs being produced in
Microsoft Excel.
Results
During the development of obesity-mediated insulin resistance,
adipocyte size increases, followed by varying degrees of fibrosis,
and inflammation [5]. Pioglitazone has well-described anti-
inflammatory properties, yet the induction of PPARc would be
expected to increase adipogenesis, lipogenesis, and increase fat cell
size. Previous studies have examined adipocyte size in response to
TZDs, but with varying results [30–34]. To examine the effects of
pioglitazone on adipose cellularity, the adipose tissue from 9
subjects was analyzed histochemically pre- and post-piloglitazone,
and image analysis software was used to determine adipocyte size
in cross section. A variety of methods can be used to stain adipose
tissue, but we used the stain for elastin, as described in methods,
since the adipocytes were well outlined, and this method allowed
the simultaneous staining for collagens and elastin. Representative
images are shown in Figure 1, where Figure 1A is adipose stained
for elastin, and Figure 1B shows the identification of adipocytes
through the image analysis software. Figures 1C and 1D are
pseudo-colored to bring out the staining for elastin (green in
Figure 1C) and collagen (red in Figure 1D).
All the adipocytes from each histological section were identified
and cross sectional area (CSA) determined (8,000–12,000 cells per
slide). As shown in Figure 2A, subjects demonstrated wide variety
of fat cell size and contained a distribution of cells varying from
500 to 8700 mm2. There was an overall decrease in the frequency
of small adipocytes and an increase in the frequency of larger
adipocyte following pioglitazone treatment (Figure 2A), such that
the average fat cell size was significantly increased following
pioglitazone treatment (Figure 2B).
The images in Figure 1 were then analyzed for ECM
components and these data were expressed in terms of the space
occupied by collagen and elastin. As shown in Figure 2C, there
was no change in overall collagen content in adipose tissue
following pioglitazone. However, pioglitazone treatment resulted
in a significant increase in adipose elastin (Figure 2D).
Previous studies have demonstrated that treatment of insulin
resistant subjects with TZDs resulted in less inflammation,
including a decrease in adipose tissue macrophage number and
cytokine expression [6,35], but no previous study has examined
the effects of TZDs on macrophage polarity. Therefore, we
examined adipose tissue macrophages immunohistochemically;
CD68 positive cells were co-stained for the M1 and M2 markers
CD86 and CD206, respectively. As described previously [1],
human adipose tissue contained many macrophages that are of a
mixed phenotype, staining with both the M1 and M2 markers, and
most macrophages demonstrate a predominant M2 phenotype. To
examine the effects of pioglitazone, the number of M1, M2, and
mixed M1/M2 macrophages were quantitated. As shown in
Figure 3A, pioglitazone treatment resulted in a decrease in total
macrophages, along with a decrease in M1 and mixed M1/M2
macrophages, with a relative increase in M2 macrophages.
Previous studies have noted decreased capillaries in adipose
tissue of insulin resistant subjects along with an increase in larger
blood vessels [2,4]. To assess the effects of pioglitazone treatment
on adipose vascularity, we counted capillaries and large vessels, as
described in Methods. As shown in Figure 3B, pioglitazone
treatment resulted in a significant increase in adipose tissue
capillaries, and no change in larger vessels.
Recent studies have noted the presence of mast cells in both
rodent and human adipose tissue [15–17]. To identify mast cells,
adipose tissue sections were stained with antibodies to tryptase, as
described in methods, and the total number of mast cells in the
whole section counted. As shown in Figure 4, mast cells were
readily identifiable in the sections, and mast cells were counted.
Mast cells can be found as isolated cells or in clusters. As shown in
Figure S2, macrophages stained with CD68 and mast cells stained
with tryptase are often found in the same region. Pioglitazone
treatment reduced mast cells in adipose tissue by 3569% (p,0.01,
Figure 4D). The subjects treated with pioglitazone were all obese
and had IGT, and therefore we wished to determine whether mast
cells are present at a higher level in obese subjects. Therefore we
compared mast cell number in a separate group of obese and lean
subjects, whose characteristics are shown in Table 1. As shown in
Figure 4C, the adipose tissue from obese subjects contained more
mast cells than the lean subjects, and were comparable to the IGT
subjects prior to pioglitazone treatment (Figure 4D). In recent
studies, we treated obese subjects with v-3 fatty acids and
demonstrated a reduction in adipose tissue macrophages [12].
Therefore, we examined mast cell number in adipose tissue of
subjects pre- and post-fish oil treatment. As shown in Figure 4E,
there was no effect of fish oil treatment on mast cells. Hence, not
all methods that result in improved adipose inflammation result in
fewer mast cells.
Discussion
Previous studies have characterized a number of pathological
changes in adipose tissue in insulin resistant subjects, including an
increase in inflammatory macrophages increased cytokine pro-
duction, increased fibrosis and a more stiff ECM, and a decrease
in capillaries [2–4,6]. Weight loss, especially in response to
bariatric surgery, is effective at improving adipose tissue inflam-
mation [36–38], but relatively few drug treatments have been
successful at improving the adipose tissue dysfunction.
A number of studies have examined the mechanism of action of
TZDs, which improve peripheral insulin sensitivity [18,39]. The
treatment of either insulin resistant or diabetic humans with either
pioglitazone or rosiglitazone reduces adipose inflammation and
cytokine expression and increases the plasma level of anti-
inflammatory adiponectin [40,41]. Fish oils contain v-3 fatty
acids, which also have PPARc agonist effects, and subjects treated
with fish oil demonstrate improvements in adipose vascularity,
inflammation and fibrosis, although no change in insulin sensitivity
[12,13,42].
The mechanism of the improved insulin sensitivity of TZDs is
likely multifactorial. On the one hand, TZDs have direct effects to
induce apoptosis in macrophages [7]. In addition, TZD treatment
results in an increase in subcutaneous adipose tissue and a
reduction ectopic lipid in muscle and liver, and this relief of muscle
and liver lipotoxicity would be expected to reduce insulin
Pioglitazone and Mast Cells
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resistance at those sites [18,43,44]. A stiff ECM has been
hypothesized to play a role in adipose dysfunction by causing
worsened hypoxia, necrosis and inflammation with adipocyte
expansion [5]. Therefore, it is important to understand the
changes in adipose tissue following pioglitazone treatment, since
Figure 2. Quantitation of images pre and post pioglitazone. A. Cell size from Figure 1B was measured in all adipocytes from a whole slide
scan, representing 8000–12000 cells, and the distribution of cell cross-sectional area relative frequency is shown before and after pioglitazone
treatment. B. Average adipocytes cross-sectional area. C. Analysis of images illustrated in Figure 1D for overall collagen. D. Analysis of images
illustrated in Figure 1C for elastin. *p,0.05 vs pre-pioglitazone.
doi:10.1371/journal.pone.0102190.g002
Figure 3. Adipose macrophage polarity and vascularity following pioglitazone treatment. A. Macrophages were characterized as M1, M2,
or mixed, as described in Methods, pre and post pioglitazone treatment. B. Adipose blood vessels were characterized as capillaries, or vessels, based
on the absence/presence of ASMA staining of a vessel wall (see Methods) and counted in adipose sections pre and post pioglitazone. *p,0.05 vs pre
pioglitazone.
doi:10.1371/journal.pone.0102190.g003
Pioglitazone and Mast Cells
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this drug improves insulin sensitivity coincident with expanded
adipose mass.
This study was designed to examine the mechanisms underlying
pioglitazone and fish oil mediated changes in adipose tissue in
insulin resistant subjects. As described above, a careful analysis of
adipocyte size employed a new image analysis methodology that
examined over 8,000 cells per histological section. Following
pioglitazone treatment, there was an increase in overall fat cell
size, with fewer small cells and more of the larger cells. Several
previous studies have examined adipose cell size with TZD
treatment, using different methods. Whereas some studies have
shown an overall net increase in cell size, which would correspond
with the increase in adipose mass [30,31], other studies have found
an increase in small adipocytes and a net decrease in fat cell size
[32,33], and another study found no change [34]. It is not clear
why there is a discrepancy between studies. In addition to
differences in patient population, there are methodological
differences. The method described herein has the advantages of
identifying cells histochemically in situ with a high level of
accuracy without a collagenase digestion and of using an image
analysis system that makes it feasible to size a large number of
cells.
In spite of this overall increase in adipocyte size induced by
pioglitazone, however, there was a reduction in macrophage
number. Previous studies have demonstrated decreased macro-
phage number following pioglitazone treatment [2,6,45], but
macrophage polarity has not been examined. In this study, there
was a shift of macrophage polarity, with fewer pro-inflammatory
M1 and relatively more M2 macrophages. Pioglitazone treatment
decreases adipose inflammation and PPARc agonists directly
induced macrophage apoptosis [7], and it is possible that M1
macrophages are more sensitive to this apoptotic effect. Further-
more, PPARc is required for alternative macrophage activation in
mice, and PPARc agonists increase mannose receptor expression
in human monocytes, suggesting that PPARc activation promotes
the M2 phenotype [46–48]. It is important to recognize the
complexity of macrophage phenotype [49], as illustrated by the
fact that many adipose macrophages had a mixed M1/M2
staining.
Several recent studies have demonstrated the presence of mast
cells in adipose tissue of both mice and humans [16,17]. Mast cells
have usually been described in relation to allergic disease and
express histamine, prostaglandins, and proteases, but these cells
also express a wide range of peptides related to inflammation,
angiogenesis and fibrosis, all of which are involved in adipose
pathology in insulin resistance [50]. In mice, the genetic depletion
of mast cells led to resistance to the deleterious metabolic effects of
a high fat diet [17]. In humans, mast cells tended to be found in
the vicinity of blood vessels and fibrotic areas, correlated with
other inflammatory markers, and were higher in diabetic humans
[16,17].
In this study, we found an increase in mast cell number with
obesity, and also examined the effects of two different drugs that
have demonstrated anti-inflammatory effects in adipose tissue.
Figure 4. Quantitation of mast cells in adipose tissue. Mast cells were identified in adipose tissue by staining for tryptase in a representative
(A) lean and (B) obese subject. C. Quantitation of mast cells in adipose tissue of lean and obese subjects. D. Mast cells in adipose tissue pre and post
pioglitazone. E. Mast cells pre and post fish oil treatment.
doi:10.1371/journal.pone.0102190.g004
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Mast cells were often found in areas with macrophages.
Pioglitazone treatment not only reduced macrophage number
and altered the polarity of the macrophages, but also reduced the
number of mast cells in adipose tissue. v-3 fatty acids have a broad
spectrum of anti-inflammatory properties [11] along with PPARc
agonist effects [13,14,42]. In a recent study, we demonstrated a
decrease in adipose tissue macrophages following 3 months of
treatment of insulin resistant subjects with fish oils [12]. However,
this decrease in macrophages from fish oils was not accompanied
by a decrease in mast cells. It is possible that the mast cell
reduction is directly dependent on the PPARc effect, and fish oils
are much less potent than pioglitazone as a PPARc agonist; it is
also possible that a longer duration of treatment or a higher dose
of fish oil would have reduced mast cells in adipose.
In previous gene expression studies, insulin resistant subject
demonstrated decreased VEGF mRNA and decreased capillary
density, and also increased expression of components of the Fc-
epsilon signaling pathway, which are involved in mast cell
activation [51]. In contrast, the opposite effects occur to these
genes in response to pioglitazone treatment, including increased
VEGF, VEGF receptor, downstream components involved with
angiogenesis, and decreased Fc-epsilon pathway components [24].
Although pioglitazone did not increase elastin gene expression,
many proteases with the ability to degrade elastin fibers were down
regulated [24]. In future studies, it would be useful to examine
elastin degradation in the adipose of insulin resistant subjects in the
context of capillary number and adipose inflammation.
These previous gene expression studies and the data described
in this paper suggest possible mechanisms for the pioglitazone-
mediated improvement in adipose tissue pathology in insulin
resistance. In spite of larger adipocytes, pioglitazone increases
expression of genes involved in capillary development, and also
increases elastin. In a previous study, we examined elastin staining
in adipose tissue and found less elastin in both fibrotic and non-
fibrotic areas in obese insulin resistant subjects [4]. An increase in
adipose tissue elastin would be predicted to allow the adipose tissue
to be more flexible and better withstand the changes in adipose
tissue architecture associated with adipocyte enlargement [5]. This
would lead to less stress on the microvasculature, a higher number
of capillaries, less hypoxia and together less adipocyte necrosis and
inflammation.
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